Global Pertussis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Pertussis Market Size

• The global pertussis market size was valued at USD 4.12 billion in 2025 and is expected to reach USD 6.42 billion by 2033, at a CAGR of 5.71% during the forecast period
• The market growth is largely fueled by the increasing incidence of pertussis (whooping cough), along with rising awareness regarding immunization programs and the importance of early disease prevention, leading to higher adoption of vaccines and treatment solutions across both developed and emerging regions
• Furthermore, growing government initiatives for routine and booster vaccination, along with rising demand for effective and long-lasting immunization solutions, is establishing pertussis vaccines as a critical component of public health programs. These converging factors are accelerating the uptake of pertussis solutions, thereby significantly boosting the industry's growth

Pertussis Market Analysis

• Pertussis, a highly contagious respiratory infection commonly known as whooping cough, remains a critical focus of global immunization programs, particularly in pediatric and vulnerable populations, due to its potential severity and periodic outbreaks
• The escalating demand for pertussis vaccines and treatments is primarily fueled by increasing incidence rates, waning immunity over time, and growing awareness regarding the importance of booster vaccinations across all age groups
• North America dominated the pertussis market with the largest revenue share of 38.7% in 2025, characterized by strong vaccination coverage, well-established healthcare infrastructure, and active government immunization initiatives, with the U.S. witnessing steady demand driven by routine and booster vaccination programs
• Asia-Pacific is expected to be the fastest growing region in the pertussis market during the forecast period due to expanding immunization coverage, rising birth rates, increasing healthcare investments, and improving awareness regarding vaccine-preventable diseases
• The parenteral segment dominated the market with a revenue share of 54.1% in 2025, primarily due to the widespread use of injectable vaccines for pertussis prevention

Report Scope and Pertussis Market Segmentation    

Pertussis Market Trends

“Increasing Focus on Vaccination Programs and Immunization Coverage”

• A significant and accelerating trend in the global Pertussis market is the growing emphasis on vaccination programs and expanded immunization coverage to prevent the spread of Pertussis, particularly among infants and vulnerable populations
• Governments and global health organizations are increasingly prioritizing routine immunization schedules, including booster doses for adolescents and adults, to maintain long-term immunity and reduce disease outbreaks
• For instance, the incorporation of combination vaccines such as DTaP (diphtheria, tetanus, and pertussis) into national immunization programs has significantly improved vaccination compliance and disease prevention
• Rising awareness regarding the importance of maternal immunization during pregnancy is also contributing to enhanced protection of newborns against pertussis
• In addition, ongoing research and development efforts are focused on improving vaccine efficacy, duration of immunity, and safety profiles to address limitations of existing vaccines
• Public health campaigns and global initiatives aimed at increasing vaccine accessibility in low- and middle-income countries are further driving market growth
• The expansion of immunization infrastructure and cold chain logistics is enabling better distribution and storage of vaccines across remote regions
• This trend toward preventive healthcare and widespread immunization is significantly shaping the growth trajectory of the pertussis market globally

Pertussis Market Dynamics

Driver

“Rising Incidence of Infectious Diseases and Government Immunization Initiatives”

• The increasing incidence of infectious diseases, including Pertussis, is a major factor driving the growth of the pertussis market worldwide
• Periodic outbreaks of pertussis, even in developed countries, highlight the need for continuous vaccination and booster immunization programs
• For instance, waning immunity over time among vaccinated individuals has led to resurgence in pertussis cases, thereby increasing demand for booster doses and improved vaccines
• Government-led immunization initiatives and funding programs are playing a critical role in enhancing vaccine coverage and accessibility
• Global organizations such as World Health Organization and UNICEF are actively supporting vaccination campaigns, particularly in underserved regions
• Increasing awareness among healthcare providers and parents regarding the severity of pertussis infection is encouraging higher vaccination uptake
• The introduction of combination vaccines and improved immunization schedules is also simplifying vaccination processes and boosting compliance rates
• Rising healthcare expenditure and improvements in public health infrastructure are further supporting market expansion
• Collectively, these factors are significantly driving demand for pertussis vaccines and related preventive healthcare solutions

Restraint/Challenge

“Waning Immunity and Vaccine Hesitancy”

• One of the key challenges in the pertussis market is the waning immunity provided by current vaccines, which may decrease over time and necessitate booster doses for sustained protection
• For instance, individuals vaccinated during childhood may experience reduced immunity in adolescence or adulthood, increasing the risk of infection and transmission
• Vaccine hesitancy among certain populations, driven by misinformation, safety concerns, or lack of awareness, continues to hinder optimal immunization coverage
• In addition, disparities in access to healthcare services and vaccination programs in low-income regions pose significant barriers to disease prevention
• Logistical challenges such as maintaining cold chain systems and ensuring timely vaccine distribution further complicate large-scale immunization efforts
• The high cost associated with vaccine development and distribution can also limit accessibility in resource-constrained settings
• Furthermore, underreporting and misdiagnosis of pertussis cases can lead to gaps in surveillance and hinder effective disease control strategies
• Addressing these challenges through improved vaccine formulations, enhanced public awareness campaigns, and strengthened healthcare infrastructure will be critical for long-term market growth

Pertussis Market Scope

The market is segmented on the basis of diagnosis, treatment, route of administration, end-users, and distribution channel.

• By Diagnosis

On the basis of diagnosis, the Pertussis market is segmented into blood tests, chest X-ray, nose or throat culture & test, and others. The nose or throat culture & test segment dominated the largest market revenue share of 36.8% in 2025, driven by its high accuracy in detecting Bordetella pertussis infection and its widespread use as a standard diagnostic method. These tests are commonly recommended by healthcare professionals due to their reliability in confirming pertussis, especially in early stages of infection. Increasing awareness about timely diagnosis and rising incidence of respiratory infections are further supporting the growth of this segment. In addition, the availability of advanced laboratory infrastructure and diagnostic capabilities in hospitals and clinics contributes to higher adoption. Governments and healthcare organizations are also emphasizing early detection to prevent disease spread, further boosting demand. The segment benefits from continuous improvements in diagnostic techniques and increasing healthcare access globally.

The blood tests segment is expected to witness the fastest CAGR of 9.3% from 2026 to 2033, driven by the growing adoption of less invasive and rapid diagnostic methods. Blood tests are gaining popularity due to their ability to detect antibodies and provide supportive diagnostic information, particularly in later stages of infection. Increasing demand for quick and convenient testing solutions is a key factor accelerating segment growth. Technological advancements in diagnostic tools and the development of more sensitive assays are further enhancing their effectiveness. In addition, the expansion of diagnostic laboratories and improved healthcare infrastructure in emerging markets are contributing to increased adoption. Rising awareness about early disease detection and improved patient compliance are also expected to support growth. The segment is anticipated to expand significantly as diagnostic technologies continue to evolve.

• By Treatment

On the basis of treatment, the Pertussis market is segmented into medication, vaccination, supportive treatments, and others. The vaccination segment dominated the largest market revenue share of 42.5% in 2025, driven by strong government immunization programs and global initiatives aimed at preventing pertussis infections. Vaccination remains the most effective strategy for controlling the spread of the disease, particularly among infants and children. Increasing awareness campaigns and mandatory vaccination policies in many countries have significantly boosted uptake. In addition, the inclusion of pertussis vaccines in routine immunization schedules supports consistent demand. Pharmaceutical companies are continuously investing in the development of improved and combination vaccines, further strengthening this segment. The rising focus on preventive healthcare and increasing healthcare expenditure also contribute to its dominance.

The medication segment is expected to witness the fastest CAGR of 8.7% from 2026 to 2033, driven by the growing need for effective treatment options for infected individuals. Antibiotics such as macrolides are commonly prescribed to manage pertussis symptoms and reduce transmission. Increasing incidence of pertussis outbreaks, particularly in regions with low vaccination coverage, is boosting demand for medications. In addition, rising awareness about early treatment and improved access to healthcare services are contributing to segment growth. Continuous research and development efforts to improve therapeutic outcomes are further supporting expansion. The segment is also benefiting from increased diagnosis rates and timely medical intervention, making it one of the fastest-growing areas in the market.

• By Route of Administration

On the basis of route of administration, the Pertussis market is segmented into oral, parenteral, and others. The parenteral segment dominated the market with a revenue share of 54.1% in 2025, primarily due to the widespread use of injectable vaccines for pertussis prevention. Parenteral administration ensures effective delivery of vaccines and rapid immune response, making it the preferred route for immunization programs. The dominance of this segment is further supported by government-led vaccination campaigns and global immunization initiatives. In addition, healthcare professionals prefer injectable routes for accurate dosing and controlled administration. Increasing focus on preventive healthcare and expanding vaccination coverage globally are key factors driving growth.

The oral segment is expected to register the fastest CAGR of 9.1% from 2026 to 2033, driven by its convenience and ease of administration, particularly for pediatric and geriatric populations. Oral medications are commonly used for treating pertussis symptoms, making them a preferred option for outpatient care. The availability of oral antibiotics and supportive drugs further supports segment growth. In addition, increasing patient preference for non-invasive treatment options is contributing to rising demand. Advancements in drug formulations and improved patient compliance are also boosting adoption. The segment is expected to witness significant growth due to its accessibility and ease of use.

• By End-Users

On the basis of end-users, the Pertussis market is segmented into hospitals, homecare, specialty clinics, and others. The hospitals segment dominated the market with a share of 47.3% in 2025, as hospitals are the primary centers for diagnosis, treatment, and vaccination of pertussis. They provide access to advanced diagnostic tools, trained healthcare professionals, and comprehensive treatment facilities. Hospitals play a crucial role in managing severe cases and administering vaccines, particularly for infants and high-risk populations. Increasing hospital admissions due to respiratory infections and rising awareness about professional healthcare services are key factors supporting segment growth. In addition, government funding and improved healthcare infrastructure further strengthen this segment’s dominance.

The homecare segment is anticipated to grow at the fastest CAGR of 9.8% from 2026 to 2033, driven by the increasing preference for home-based treatment and recovery. Patients with mild to moderate symptoms often opt for homecare due to convenience and cost-effectiveness. The availability of oral medications and supportive care options enables effective treatment outside hospital settings. In addition, the rise of telehealth services and remote consultations is facilitating better disease management at home. Growing awareness about self-care and improved access to healthcare resources are further boosting segment growth. The shift towards outpatient care is expected to significantly contribute to this segment’s expansion.

• By Distribution Channel

On the basis of distribution channel, the Pertussis market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment dominated the market with a revenue share of 45.9% in 2025, driven by the high volume of vaccinations and treatments administered in hospital settings. Hospital pharmacies ensure the availability of essential medications and vaccines, particularly for inpatient care and immunization programs. They play a crucial role in maintaining drug supply chains and supporting healthcare providers. Increasing patient visits to hospitals and rising vaccination rates are key factors contributing to segment growth. In addition, government initiatives and institutional procurement further strengthen this segment.

The online pharmacy segment is expected to witness the fastest CAGR of 11.1% from 2026 to 2033, fueled by the rapid growth of digital healthcare platforms and e-commerce. Online pharmacies offer convenience, home delivery, and competitive pricing, making them increasingly popular among consumers. The rising adoption of smartphones and internet penetration is further driving this segment. In addition, the COVID-19 pandemic accelerated the shift toward online healthcare services, a trend that continues to persist. Improved regulatory frameworks and advancements in digital infrastructure are also supporting market expansion. The segment is expected to grow significantly as consumers increasingly prefer convenient and contactless purchasing options.

Pertussis Market Regional Analysis

• North America dominated the pertussis market with the largest revenue share of 38.7% in 2025, characterized by strong vaccination coverage, well-established healthcare infrastructure, and active government immunization initiatives
• The region benefits from high awareness regarding vaccine-preventable diseases such as Pertussis, along with structured immunization schedules for infants, adolescents, and adults. Robust public health policies, strong presence of leading vaccine manufacturers, and favorable reimbursement frameworks are further supporting market growth
• In addition, the increasing focus on booster vaccination programs and maternal immunization strategies is contributing significantly to sustained demand in the region

U.S. Pertussis Market Insight

The U.S. pertussis market captured the largest revenue share in 2025 within North America, driven by consistent demand for routine and booster vaccination programs. The country demonstrates high vaccination coverage supported by strong government initiatives and recommendations from health authorities such as the Centers for Disease Control and Prevention. Increasing awareness regarding the importance of immunization across all age groups, including pregnant women, is further boosting vaccine uptake. In addition, the presence of advanced healthcare infrastructure, ongoing surveillance programs, and continuous research and development activities are key factors propelling market growth.

Europe Pertussis Market Insight

The Europe pertussis market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by strong national immunization programs and increasing awareness of infectious diseases. Rising incidences of pertussis outbreaks in certain regions have reinforced the importance of booster vaccinations and continuous monitoring. Government initiatives, along with recommendations from organizations such as the European Centre for Disease Prevention and Control, are encouraging higher vaccination coverage. In addition, improved access to healthcare services and public health campaigns are supporting market expansion across the region.

U.K. Pertussis Market Insight

The U.K. pertussis market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by strong support from national immunization programs and increasing awareness regarding maternal vaccination. The government’s proactive approach toward protecting infants through vaccination during pregnancy is a key growth factor. Furthermore, continuous monitoring of pertussis cases and public health campaigns are encouraging timely vaccination and booster dose administration.

Germany Pertussis Market Insight

The Germany pertussis market is expected to expand at a considerable CAGR during the forecast period, supported by a well-established healthcare system and high vaccination compliance rates. Increasing awareness regarding infectious disease prevention and strong emphasis on routine immunization schedules are contributing to market growth. In addition, the country’s focus on preventive healthcare and availability of advanced vaccine options are further strengthening the market landscape.

Asia-Pacific Pertussis Market Insight

The Asia-Pacific pertussis market is expected to grow at the fastest CAGR during the forecast period, driven by expanding immunization coverage, rising birth rates, increasing healthcare investments, and improving awareness regarding vaccine-preventable diseases. Governments across countries such as China and India are actively strengthening national immunization programs to improve vaccination rates. Rising population levels and increasing number of newborns are significantly contributing to the demand for pertussis vaccines. Improvements in healthcare infrastructure and access to vaccination services are enabling broader reach, particularly in rural and underserved areas. Public health initiatives and collaborations with global organizations are further supporting large-scale immunization drives. The growing focus on preventive healthcare and increasing government spending are key factors accelerating regional market growth.

Japan Pertussis Market Insight

The Japan pertussis market is gaining momentum due to high awareness regarding infectious diseases and strong adherence to vaccination schedules. The country’s advanced healthcare system and focus on preventive care contribute to high immunization rates. In addition, the aging population and emphasis on booster vaccinations for adults are supporting sustained demand in the market. Continuous surveillance and government-led initiatives further strengthen disease prevention efforts.

China Pertussis Market Insight

The China pertussis market accounted for the largest market revenue share in Asia-Pacific in 2025, attributed to expanding immunization programs, a large population base, and increasing healthcare investments. Rising awareness regarding vaccine-preventable diseases and strong government initiatives to improve vaccination coverage are driving market growth. In addition, the presence of domestic vaccine manufacturers and increasing accessibility to affordable vaccines are further supporting the expansion of the pertussis market in China.

Pertussis Market Share

The Pertussis industry is primarily led by well-established companies, including:

• GSK plc (U.K.)
• Sanofi S.A. (France)
• Pfizer Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Johnson & Johnson (U.S.)
• AstraZeneca plc (U.K.)
• Serum Institute of India Pvt. Ltd. (India)
• Bharat Biotech (India)
• Panacea Biotec Ltd. (India)
• Biological E Limited (India)
• CSL Limited (Australia)
• Emergent BioSolutions Inc. (U.S.)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Astellas Pharma Inc. (Japan)
• Daiichi Sankyo Company, Limited (Japan)
• Sinovac Biotech Ltd. (China)
• Sinopharm Group Co., Ltd. (China)
• Zydus Lifesciences Ltd. (India)
• Bavarian Nordic A/S (Denmark)
• Valneva SE (France)

Latest Developments in Global Pertussis Market

• In March 2021, researchers in China initiated and reported progress from Phase I/II clinical trials of recombinant vaccine candidates incorporating pertussis antigens, aimed at enhancing immune response consistency and overcoming limitations associated with traditional whole-cell and acellular vaccines. This development reflects growing global efforts to modernize pertussis vaccine technology through advanced recombinant platforms
• In June 2022, the World Health Organization (WHO), through its Strategic Advisory Group of Experts (SAGE), undertook a comprehensive review of pertussis vaccination strategies, including infant immunization schedules, booster dose requirements, and maternal vaccination approaches, with the objective of strengthening global immunization policies and addressing persistent disease burden
• In September 2023, multiple countries across Europe and North America expanded maternal pertussis vaccination programs, supported by emerging clinical evidence demonstrating that immunization during pregnancy significantly enhances passive immunity transfer to newborns and reduces infant morbidity and mortality associated with whooping cough
• In February 2024, the Centers for Disease Control and Prevention (CDC) reported a notable resurgence in pertussis cases in the United States, with infection rates increasing sharply compared to the previous year, highlighting declining vaccination coverage and reinforcing the urgency for improved booster uptake and public health interventions
• In April 2025, public health surveillance data in the United States indicated that pertussis cases had more than doubled year-over-year, signaling a continued upward trend in disease incidence and emphasizing the need for strengthened immunization campaigns and enhanced awareness programs targeting vulnerable populations
• In November 2025, researchers at Trinity College Dublin announced the development of a novel intranasal pertussis vaccine candidate that demonstrated the ability to block both infection and transmission in preclinical studies, representing a significant advancement over current vaccines that primarily reduce symptoms but have limited impact on transmission dynamics
• In November 2025, scientists reported progress in developing an antibiotic-inactivated Bordetella pertussis (AIBP) vaccine platform, which showed complete protective efficacy in preclinical evaluations, offering a promising next-generation approach to respiratory disease prevention with potential advantages in safety and immune response durability
• In December 2025, BioNet-Asia introduced VacPertagen, a novel pertussis booster vaccine candidate designed for older children and pregnant women, demonstrating rapid antibody generation and potential to enhance passive immunity transfer to infants, thereby strengthening preventive strategies in high-risk population
• In October 2025, global surveillance studies highlighted the increasing emergence of macrolide-resistant Bordetella pertussis strains across several regions, raising concerns regarding reduced effectiveness of standard antibiotic therapies and underscoring the need for continued innovation in both vaccine development and treatment options

SKU-53985